Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Dimension Therapeutics, Inc. (DMTX)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Sep-30-17 | Jun-30-17 | Mar-31-17 | Dec-31-16 | Sep-30-16 | Jun-30-16 | Mar-31-16 | Dec-31-15 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues | 4.5 | 4.4 | 3.6 | 4.1 | 2.8 | 2.4 | 2.2 | 2.4 |
| Revenue growth | 62.2% | 84.3% | 64.0% | 75.6% | 34.0% | 36.1% | 38.4% | 67.2% |
| Cost of goods sold | -22.0 | -17.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 26.5 | 21.3 | 3.6 | 4.1 | 2.8 | 2.4 | 2.2 | 2.4 |
| Gross margin | 591.3% | 488.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative [+] | 5.3 | 2.6 | 3.4 | 3.3 | 3.3 | 3.2 | 2.9 | 2.6 |
| General and administrative | 5.3 | 2.6 | 3.4 | 3.3 | 3.3 | 3.2 | 2.9 | 2.6 |
| Research and development | 16.1 | 14.1 | 13.7 | 13.9 | 13.8 | 11.2 | 8.8 | 8.8 |
| Other operating expenses | 21.5 | 16.7 | | | | | | |
| EBITDA [+] | -15.9 | -11.5 | -13.0 | -12.5 | -13.9 | -11.7 | -9.3 | -8.8 |
| EBITDA growth | 14.5% | -1.4% | 39.3% | 42.4% | 32.8% | 19.6% | 78.0% | 94.9% |
| EBITDA margin | -354.4% | -263.8% | -358.9% | -303.2% | -501.9% | -492.7% | -422.7% | -374.0% |
| Depreciation and amortization | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.2 | 0.2 |
| EBIT [+] | -16.4 | -12.1 | -13.5 | -13.1 | -14.3 | -12.1 | -9.5 | -9.0 |
| EBIT growth | 14.5% | -0.3% | 41.8% | 45.0% | 34.7% | 21.7% | 77.8% | 95.8% |
| EBIT margin | -366.4% | -276.1% | -373.9% | -316.2% | -519.2% | -510.5% | -432.5% | -382.9% |
| Non-recurring items | 0.6 | 0.3 | | | | | | |
| Interest income, net [+] | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest expense | | | | | | | | 0.0 |
| Interest income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other income (expense), net | | | | | -0.1 | | | |
| Pre-tax income | -16.9 | -12.3 | -13.5 | -13.0 | -14.4 | -12.1 | -9.5 | -9.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -16.9 | -12.3 | -13.5 | -13.0 | -14.4 | -12.1 | -9.5 | -9.0 |
| Net margin | -378.3% | -281.7% | -372.9% | -315.2% | -520.1% | -510.3% | -431.2% | -383.7% |
| |
| Basic EPS [+] | ($0.68) | ($0.49) | ($0.54) | ($0.52) | ($0.58) | ($0.49) | ($0.38) | ($0.45) |
| Growth | 17.4% | 1.3% | 41.1% | 15.7% | -78.9% | -81.1% | -72.7% | -64.9% |
| Diluted EPS [+] | ($0.68) | ($0.49) | ($0.54) | ($0.52) | ($0.58) | ($0.49) | ($0.38) | ($1.14) |
| Growth | 17.4% | 1.3% | 41.1% | -54.0% | -78.9% | -81.1% | -72.7% | -11.6% |
| |
| Shares outstanding (basic) [+] | 25.1 | 25.0 | 25.0 | 25.0 | 24.9 | 24.9 | 24.9 | 20.0 |
| Growth | 0.5% | 0.4% | 0.5% | 24.7% | 538.1% | 541.5% | 545.0% | 454.6% |
| Shares outstanding (diluted) [+] | 25.1 | 25.0 | 25.0 | 24.9 | 24.9 | 24.9 | 24.9 | 7.9 |
| Growth | 0.5% | 0.4% | 0.5% | 213.4% | 538.1% | 541.5% | 545.0% | 120.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|